The Value of Ammonia as a Biomarker in Patients with Cirrhosis
Seminars in Liver Disease · 2024-08 · 44 (03) · 356-368
DOI: 10.1055/a-2378-8942 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, online erschienen am 03.09.2024. Verfasst von Maria Pilar Ballester und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Unit, Digestive Disease Department, Hospital Clínico Universitario de Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Ammonia, Liver Cirrhosis, Biomarkers, Hepatic Encephalopathy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Ammonia is a product of amino acid metabolism that accumulates in the blood of patients with cirrhosis and plays a pivotal role in the pathogenesis of hepatic encephalopathy (HE). Despite being one of the main drivers of brain dysfunction, for many years international societies stated that increased blood ammonia does not add any diagnostic, staging, or prognostic value for HE in patients with cirrhosis. Nonetheless, in the last decades, evidence is emerging that supports the utility of ammonia for risk stratification, but its role in guiding HE diagnosis, staging, and treatment is unclear and there is equipoise in its use in clinical practice. This review provides the latest evidence on the value of ammonia as a biomarker in patients with cirrhosis. Although correct measurement of ammonia requires disciplined sample collection, it provides extremely useful clinical guidance for the diagnosis of HE, offers prognostic information, and it defines a therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hepatology Unit, Digestive Disease Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
- Department of Gastroenterology and Hepatology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
- Department of Internal Medicine, Ege University Faculty of Medicine, Izmir, Turkey.
- Hepatology Unit, Department of Infectious Disease, Southern Medical University, Nanfang Hospital, Guangzhou, China.
- Liver Failure Group, Institute for Liver and Digestive Health, University College London, London, United Kingdom.
- European Foundation for the Study of Chronic Liver Failure (EF Clif), Barcelona, Spain.
Zitieren
APA
Ballester, M. P., Durmazer, E. N., Qi, T., & Jalan, R. (2024). The Value of Ammonia as a Biomarker in Patients with Cirrhosis. Seminars in Liver Disease, 44(03), 356-368. https://doi.org/10.1055/a-2378-8942
Vancouver
Ballester MP, Durmazer EN, Qi T, Jalan R. The Value of Ammonia as a Biomarker in Patients with Cirrhosis. Seminars in Liver Disease. 2024;44(03):356-368. doi:10.1055/a-2378-8942
BibTeX
@article{Ballester2024,
author = {Ballester, Maria Pilar and Durmazer, Esra Nur and Qi, Tingting and Jalan, Rajiv},
title = {The Value of Ammonia as a Biomarker in Patients with Cirrhosis},
journal = {Seminars in Liver Disease},
year = {2024},
volume = {44},
number = {03},
pages = {356--368},
doi = {10.1055/a-2378-8942}
}
EUVIMED